Boston Scientific Q1 beats: $3.856B sales +13.8%, adj EPS $0.56 vs $0.50-0.52 guide; raises FY outlook

BOSTON SCIENTIFIC CORP

2024-Q1 EPS reported $0.33 revenue$3,856,000,000

GAAP net income $495M ($0.33 EPS) vs guide $0.29-0.31; adjusted EPS $0.56 vs $0.47 YoY and $0.50-0.52 guide.
Net sales $3.856B, +13.8% reported (guide 7.5-9.5%), +15.0% operational, +13.1% organic (guide 7-9%).
Cardiovascular +15.9% reported, MedSurg +10.3%; U.S. +12.7%, APAC +18.3%, Emerging Markets +22.6%.
Launched FARAPULSE PFA in U.S.; FDA approved AGENT Drug-Coated Balloon; €2.0B notes for Axonics acquisition.
FY2024 guidance: sales growth 11-13% reported, 10-12% organic; adj EPS $2.29-2.34; Q2 adj EPS $0.57-0.59.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BOSTON SCIENTIFIC CORP reported the first quarter ended March 31, 2024 results: revenue $3.856 billion, net income $495 million or $0.33 per share, EPS $0.56 for the period.

Period: the first quarter ended March 31, 2024
Revenue: $3.856 billion
Net income: $495 million or $0.33 per share
EPS: $0.56 for the period
Result: reported results

Exact text from the filing

Document Boston Scientific Announces Results for First Quarter 2024 Marlborough, Mass. (April 24, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational 1 basis and 13.1 percent on an organic 2 basis, all compared to the

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-24-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.